Q: Which equation describes the elimination half-life ($$t_{1/2}) of a $$drug, and how does this relate to poor metabolizers?

$$t_{1/2} = \frac{0.693 \times V_{d}}{Cl}$$

Question 1

Based on the plasma concentration-time curves for different metabolizer phenotypes, which metabolizer is at the highest risk for drug toxicity when given a standard dose of a drug metabolized by CYP2C9?

Accepted Answer

Poor Metabolizer (PM)

Question 2

A patient with the CYP2C9 genotype *1A/*2 is prescribed a standard dose of warfarin. Which of the following best describes their expected drug metabolism and plasma concentration profile?

Accepted Answer

They will metabolize warfarin slowly, with a risk of higher plasma levels and possible toxicity.

Question 3

Which of the following equations correctly represents the area under the curve (AUC) for plasma drug concentration over time, and why is this clinically significant for poor metabolizers?

Accepted Answer

$$AUC = \int_{0}^{\infty} C(t) \, dt$$

Question 4

A patient is an ultra-rapid metabolizer (UM) for CYP2D6 and is prescribed codeine, a pro-drug. What is the most likely clinical outcome?

Accepted Answer

The patient will have a higher risk of toxicity due to rapid conversion to the active drug.

Question 5

Which resource provides standardized nomenclature for star (*) allele definitions in pharmacogenes?

Accepted Answer

PharmVar

Question 6

A patient with the genotype CYP2C19 *2B/*3A is prescribed clopidogrel, a pro-drug. What is the most likely clinical consequence?

Accepted Answer

The patient will slowly activate clopidogrel, possibly resulting in therapeutic failure.

Question 7

Which of the following best describes the difference in clinical management for a poor metabolizer (PM) versus an ultra-rapid metabolizer (UM) when prescribing a standard drug (not a pro-drug)?

Accepted Answer

PMs are at risk for toxicity, UMs are at risk for subtherapeutic effects.

Question 8

Which equation describes the elimination half-life ($$t_{1/2}) of a $$drug, and how does this relate to poor metabolizers?

Accepted Answer

$$t_{1/2} = \frac{0.693 	imes V_{d}}{Cl}$$

Question 9

A patient’s pharmacogenomic report shows CYP2D6 *3A/*4A. Which metabolizer phenotype does this correspond to, and what is the clinical implication for a drug metabolized by CYP2D6?

Accepted Answer

Poor Metabolizer (PM); increased risk of toxicity at standard doses.

Question 10

Which of the following statements about pro-drugs is correct?

Accepted Answer

Ultra-rapid metabolizers activate pro-drugs quickly, increasing risk of toxicity.

Question 11

Which clinical resource provides peer-reviewed, evidence-based guidelines for using genetic test results to optimize drug therapy?

Accepted Answer

CPIC Guidelines

Question 12

A patient is prescribed amitriptyline, which is metabolized by CYP2D6. If the patient is an intermediate metabolizer (IM), what adjustment might be necessary?

Accepted Answer

Decrease the dose to avoid toxicity.

Question 13

Which of the following best explains why poor metabolizers (PMs) do not completely lack drug metabolism?

Accepted Answer

PMs have alternative, less efficient metabolic pathways.

Question 14

A patient with CYP2C19 *1A/*1A is prescribed omeprazole. What is the expected metabolizer phenotype and clinical response?

Accepted Answer

Extensive Metabolizer (EM); normal metabolism and response.

Question 15

Which of the following drugs is a substrate for CYP2C9 and may require dose adjustment in poor metabolizers?

Accepted Answer

Ibuprofen

Question 16

A patient is an ultra-rapid metabolizer (UM) for CYP2D6 and is prescribed metoprolol, a standard drug. What is the most likely clinical outcome?

Accepted Answer

The patient will have subtherapeutic drug levels and reduced efficacy.

Question 17

Which of the following best describes the role of PharmGKB in pharmacogenomics?

Accepted Answer

It curates evidence about how genetic variation affects drug response.

Question 18

A patient with CYP2C9 *1A/*6 is prescribed celecoxib. What is the expected metabolizer phenotype and clinical implication?

Accepted Answer

Intermediate Metabolizer (IM); consider dose reduction.

Question 19

Which of the following statements is true regarding the clinical consequences of metabolizer status for pro-drugs?

Accepted Answer

Poor metabolizers may not achieve therapeutic effect due to slow activation.

Genetic Variation and Its Clinical Impact on Drug Metabolism: Pharmacogenomics and CYP450 Enzymes

Study Guide - Practice Questions

Study Guide - Flashcards